

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/00, 31/215, 31/19, 31/195, 31/455, 31/20, 45/06, 31/425	A1	(11) International Publication Number: WO 99/38498 (43) International Publication Date: 5 August 1999 (05.08.99)
(21) International Application Number: PCT/US98/25495 (22) International Filing Date: 2 December 1998 (02.12.98) (30) Priority Data: 60/072,912 28 January 1998 (28.01.98) US (71) Applicant (for all designated States except US): WARNER-LAMBERT COMPANY [US/US]; 201 Tabor Road, Morris Plains, NJ 07950 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): BISGAIER, Charles, Larry [US/US]; 3605 Tanglewood Drive, Ann Arbor, MI 48105 (US). EMMERLING, Mark, Richard [US/US]; 1237 N. Freer Road, Chelsea, MI 48118 (US). (74) Agents: RYAN, M., Andrea; Warner-Lambert Company, 201 Tabor Road, Morris Plains, NJ 07950 (US) et al.		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: METHOD FOR TREATING ALZHEIMER'S DISEASE (57) Abstract <p>The present invention provides a method for treating or preventing the onset of Alzheimer's Disease comprising administering to a mammal in need thereof an Alzheimer's Disease-preventing or treating amount of a plasma-triglyceride level-lowering agent. Optionally, the plasma-triglyceride level-lowering agent can be co-administered with a cholesterol level-lowering agent.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD FOR TREATING ALZHEIMER'S DISEASE

BACKGROUND OF THE INVENTION

The present invention relates to the field to therapeutic treatments of Alzheimer's disease.

5

SUMMARY OF THE RELATED ART

Alzheimer's Disease (AD) is characterized by the accumulation of insoluble, 10 nm filaments containing β -amyloid ($A\beta$) peptides, localized in the extracellular space of the cerebral cortex and vascular walls. These 40 or 42 amino acid long $A\beta$ peptides are derived from the larger β -amyloid precursor protein (β APP) through the endopeptidase action of β and γ secretases. In addition, the post-translational action of putative aminopeptidases results in a heterogeneous shortening of the 40 or 42 amino acid long $A\beta$ peptides that either terminate at residue 40 or 42 and, therefore, are designated as $A\beta$ N-40 and $A\beta$ N-42. In familial forms of AD, the pathological appearance of the $A\beta$ peptides in the brain is driven by the presence of mutations in the β APP gene or in the genes coding for the proteins presenilin 1 and 2.

15

Sporadic AD accounts for more than 95% of the known AD cases. Its etiology, however, remains obscure. An accepted view is that sporadic AD results from the interplay between an individual's genetic factors and the environment, leading to the deposition of $A\beta$, neurodegeneration, and dementia. Despite this emerging perspective, few efforts have been made in identifying factors responsible for $A\beta$ accumulation in the brain.

20

Epidemiological investigations clearly indicate that cardiovascular diseases increase the risk of developing AD. Several studies have also demonstrated a high incidence of often neglected cardiovascular problems in the AD population. Moreover, those with cardiovascular disease, but no overt dementia, frequently exhibit AD-like neuropathological lesions in their brains.

25

Several lines of evidence suggest that cholesterol and cholesterol metabolism might influence susceptibility to AD. Two previous clinical studies showed that total serum or LDL cholesterol was elevated in patients with AD. Moreover, individuals who are ApoE ϵ 4, a well recognized risk factor for cardiovascular disease and AD, also tend to manifest hypercholesterolemia. In addition, the incidence of AD appears to be higher in countries with high fat and high caloric diets, and decreased in populations ingesting diets that decrease cardiovascular disease. Epidemiological investigations have further demonstrated that the risk for AD was greater in individuals with high cholesterol levels, and that the onset of AD occurred earlier in those individuals who were ApoE ϵ 4 with high serum cholesterol. It may also be significant that polymorphic variations in genes coding for the lipoprotein-like receptor protein (LRP) and apolipoprotein ApoE4 might increase susceptibility to AD.

WO 95/06470 discloses methods for treating, arresting the development of, and preventing Alzheimer's disease by regulating the amount of ApoE isoform 4 circulating in the bloodstream and in the brain, comprising employing an HMG-CoA reductase inhibitor, e.g., lovastatin, simvastatin, pravastatin, and fluvastatin.

WO 97/48701 discloses 4,1-benzoxazepines and 4,1-benzothiazepines as squalene synthase inhibitors and propose their use as anti-AD agents.

Studies have shown that pharmaceutical reduction of blood cholesterol with statins or bile sequestrants reduce vascular and cardiac disease. Similarly, high blood triglyceride levels are also associated with certain types of vascular and cardiac diseases ("VCD"). It has heretofore been unknown, however, whether reduction of plasma triglycerides delays onset of AD.

SUMMARY OF THE INVENTION

The present invention comprises a new method for treating and preventing the onset of Alzheimer's Disease. In one aspect, a method of treating AD is provided, the method comprising administering to a mammal suffering from AD an AD-alleviating amount of an agent that lowers the mammal's blood

triglyceride level or otherwise regulates lipids. In another aspect, a method of preventing the onset of AD is provided, the method comprising administering to a mammal an AD-preventing amount of an agent that lowers the mammal's blood triglyceride level.

5 In another aspect of the invention, methods of treating and preventing AD are provided, which methods comprise administering to a mammal a combination of agents that lower the mammal's blood triglyceride level and its cholesterol level.

10 In another aspect of the invention, methods of treating and preventing AD are provided, which methods comprise administering to a mammal a combination of agents that lower the mammal's blood triglyceride level and its LDL-cholesterol (LDL-C) level and raise its HDL level.

15 In yet another aspect of the invention, methods of treating and preventing AD are provided, which methods comprise administering to a mammal an agent that raises the mammal's HDL cholesterol level. In another aspect, the HDL cholesterol (HDL-C) level-raising agent is administered in combination with an LDL-C cholesterol lowering agent.

20 The foregoing merely summarizes certain aspects of the invention and is not intended, nor should it be construed, as limiting the invention in any manner. All patents and other publications cited herein are hereby incorporated by reference in their entirety.

BRIEF DESCRIPTION OF FIGURES

Figure 1 shows the differences in LDL cholesterol levels between AD patients and non-AD control patients (ND).

25 Figure 2 shows the comparison of brain grey matter cholesterol in AD patients and in non-AD patients (2A), and the comparison of brain white matter cholesterol in AD patients and in non-AD patients (2B).

30 Figure 3A shows the amount of insoluble fibrillar A β N-40 in brains of AD patients segregated by ApoE genotype (i.e., ϵ 3, ϵ 4), compared to non-AD controls (ND), also segregated by ApoE genotypes.

Figure 3B shows the amount of insoluble fibrillar A β N-42 in brains of AD patients, compared to non-AD controls (ND).

Figure 3C shows the amount of total fibrillar A β protein in brains of AD patients, compared to non-AD controls (ND).

5 Figure 4 shows the correlations between brain fibrillar A β N-42 and serum lipoproteins and ApoB. The relationships between brain A β N-42 with serum total cholesterol (4A), LDL cholesterol (4B), apolipoprotein B (4C) and HDL cholesterol (4D) in control (C) and AD subjects are shown.

10 Figure 5 shows the dose-dependent inhibition of β -amyloid protein in CHO cell culture caused by several statin cholesterol lowering agents, namely mevastatin, lovastatin, pravastatin, and simvastatin.

Figure 6 shows the activity of CI-1011 (avasimibe), CI-1027, CI-719 (gemfibrozil), and PD 69405 to reduce β -amyloid concentrations in CHO cells.

15 Figure 7 shows the effect on the concentration of β -amyloid protein N-42 and N-40 in animal brains following dosing with a lipid regulating agent (simvastatin, S) relative to controls (C).

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS


20 The present invention comprises a new method for treating and preventing or delaying the onset of Alzheimer's Disease. It is born by the observation that risk factors for cardiovascular disease can have a profound impact on the expression of A β in AD brains. The data presented herein implicates ApoE ϵ 4 status as the major determinant in the expression of A β N-40. Also, independent of ApoE genotype, higher levels of plasma cholesterol in the form of LDL are related to higher concentrations of A β N-42 in the AD brain. In addition, 25 the data show a benefit of having an elevated ratio of HDL-C relative to very low density lipoprotein cholesterol (VLDL-C), plus low density lipoprotein cholesterol (LDL-C), in reduction of AD. The data clearly establishes the participation of plasma cholesterol in the pathophysiology of AD. Other studies have shown that other neurological disorders, such as vascular dementia and stroke, are related to

hypercholesterolemia and hypertension. In these latter diseases, retrospective and prospective epidemiological studies have demonstrated that the use of anti-hypertensive agents or control of plasma cholesterol levels, through diet and drugs, have decreased the morbidity and mortality caused by these diseases. Thus, regulation of cardiovascular risk factors can also offer an as yet unexplored avenue to prevent or at least delay the occurrence of Alzheimer's Disease.

In view of the foregoing, therefore, in one aspect of the invention, a method of treating Alzheimer's Disease is provided, the method comprising administering to a mammal suffering from Alzheimer's Disease an Alzheimer's Disease-alleviating amount of a plasma triglyceride level-lowering agent. Numerous triglyceride level-lowering agents are known, and include, but are not limited to, fibrates (e.g., clofibrate, gemfibrozil (CI-719), fenofibrate, ciprofibrate, and bezafibrate), niacin, carboxyalkethers, thiazolinediones, eicosapentaenoic acid (EPA) and EPA-containing compositions (e.g., Max EPA, SuperEPA).

Thiazolinediones useful in the present invention include, for example, darglitazone, pioglitazone, BRL49653 (rosiglitazone), and troglitazone.

Carboxyalkylethers useful in the invention are described in U.S. Patent No. 5,648,387. Specifically, such compounds have the structure of Formula I



wherein

n and m independently are integers from 2 to 9;

R₁, R₂, R₃, and R₄ independently are C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl,

and R₁ and R₂ together with the carbon to which they are attached, and

R₃ and R₄ together with the carbon to which they are attached, can

complete a carbocyclic ring having from 3 to 6 carbons;

Y₁ and Y₂ independently are COOH, CHO, tetrazole, and COOR₅ where R₅ is

C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl;


-6-

and where the alkyl, alkenyl, and alkynyl groups may be substituted with one or two groups selected from halo, hydroxy, C₁-C₆ alkoxy, and phenyl.

Preferred carboxyalkylethers for use in the invention have the above formula wherein n and m are the same integer, and wherein R₁, R₂, R₃, and R₄ each are alkyl.


Further preferred carboxyalkylethers are those in which Y₁ and Y₂ independently are COOH or COOR₅ where R₅ is alkyl.

The most preferred carboxyalkylethers for use in the invention have the formula




wherein n and m are each an integer selected from 2, 3, 4, or 5, ideally 4 or 5.

An especially preferred carboxyalkylether for use in the invention is CI-1027, which has the formula




Another group of lipid regulators which lower triglycerides and which can be used according to this invention are inhibitors of acyl-coenzyme A:cholesterol acyltransferase (ACAT). Such ACAT inhibitors are well-known, for example, as described in U.S. Patent No. 5,491,172. These compounds have the general structure



wherein X and Y are O, S, or (CR'R'')_n, n is 1 to 4, R is hydrogen, alkyl or benzyl, R₁ and R₂ include aryl and cycloalkyl. One compound from within this group is especially preferred, namely 2,6-bis(1-methylethyl)phenyl[2,4,6-tris(1-methylethyl)phenyl]acetyl]sulfamate, now generically known as avasimibe, and also known as CI-1011.

Other commonly available plasma triglyceride-lowering agents can also be employed. One such compound is PD 69405, which has the structure



In another embodiment of this aspect of the invention, a method for treating AD is provided in which the plasma triglyceride level-lowering agent is co-administered with an effective plasma cholesterol lowering amount of a plasma cholesterol level-lowering agent. Many such plasma cholesterol-level-lowering agents useful in this embodiment are known and include, but are not limited to, statins (e.g., lovastatin (U.S. Patent No. 4,231,938), mevastatin (U.S. Patent No. 3,983,140), simvastatin (U.S. Patent No. 4,444,784), atorvastatin, cerivastatin (U.S. Patent No. 5,502,199 and EP 617019), velostatin (U.S. Patent Nos. 4,448,784 and 4,450,171), flurastatin (U.S. Patent No. 4,739,073), dalvastain (EP Appln. Publn. No. 738510 A2), fluindostatin (EP Appln. Publn. No. 363934 A1) and pravastatin (U.S. Patent No. 4,346,227), the bile acid sequestrants (e.g., cholestyramine and colestipol), and agents that block intestinal cholesterol absorption, e.g., β -sitosterol, SCH48461, CP-148,623 (Harris et al., *Clin. Pharm. Therap.*, 1997;61:385), saponins, neomycin, and ACAT (acyl-CoA:cholesterol acyltransferase) inhibitors. The patent art is rich with compounds that inhibit cholesterol biosynthesis, as evidenced by U.S. Patent Nos. 5,468,771, 5,447,717, 5,385,932, 5,376,383, 5,369,125, 5,362,752, 5,359,096, 5,326,783, 5,322,855, 5,317,031, 5,310,949, 5,302,604, 5,294,627, 5,286,895, 5,284,758, 5,283,256, and 5,278,320.

In a second aspect of the invention, a method of preventing the onset of Alzheimer's Disease is provided, the method comprising administering to a mammal an Alzheimer's Disease-preventing amount of a plasma triglyceride

level-lowering agent. Such plasma triglyceride level-lowering agents are known in the art and include those recited above.

5 In another embodiment of this aspect of the invention, a method of preventing the onset of AD is provided in which the plasma triglyceride level-lowering agent is co-administered with an effective plasma cholesterol-lowering amount of a plasma cholesterol level-lowering agent. Many such plasma cholesterol-level-lowering agents are useful in this embodiment are known and include those recited previously.

10 In another aspect of the invention, methods of treating and preventing AD are provided, which methods comprise administering to a mammal a combination of agents that lower the mammal's blood triglyceride level and its LDL-cholesterol (LDL-C) level and raise its HDL level. Agents that reduce LDL-C levels are known and include HMG-CoA reductase (HMGR) inhibitors, especially the statins such as atorvastatin, lovastatin, simvastatin, pravastatin, rivastatin, 15 mevastatin, fluindostatin, cerivastatin, velostatin, fluvastatin, dalvastain, as well as dihydrocompactin (U.S. Patent No. 4,450,171), compactin (U.S. Patent No. 4,804,770), and neomycin. Atorvastatin calcium is particularly preferred (U.S. Patent No. 5,273,995). HDL level-increasing drugs include gemfibrozil and simvastatin, and especially the carboxyalkylethers mentioned above, for example 20 CI-1027.

In yet another aspect of the invention, methods of treating and preventing AD are provided, which methods comprise administering to a mammal an agent that raises the mammal's HDL cholesterol level. In another aspect the HDL cholesterol (HDL-C) level-raising agent is administered in combination with an 25 LDL-C lowering agent.

Besides the agents expressly recited herein, there are many known agents useful in the various aspects of the invention, many of which are described in *The Merck Index* (Eleventh Edition) (Budavari et al., Eds., Merck & Co., Inc., Rahway, NJ) and the Physician's Desk Reference (Medical Economics Data 30 Production Co., Montvale NJ). Pharmaceutically acceptable salts of the compounds useful in the invention can also be used. It will also be clear to those skilled in the art that more than one agent can be used for any particular purpose, as can pharmaceutically acceptable compositions comprising one or more agents.

The amounts of agents suitable for use in the various aspects of the invention are readily and routinely determinable by those skilled in the art using standard, art recognized methods. For example, to determine effective and optimal amounts of triglyceride level-lowering agents useful for treating AD, several
5 groups of patients suffering from AD should be followed. One group, the control group, is to be administered a placebo. The remaining groups are administered varying amounts of a triglyceride level-lowering agent, and the cognitive skills of
the individuals in each of the groups monitored to determine which group or groups manifest better cognitive skills compared to the control group. Similar
10 routine studies can be conducted to determine effective and optimal amounts of such agents for preventing and/or delaying the onset of AD, with and without the co-administration of a cholesterol level-lowering agent.

In general, however, amounts of triglyceride level-lowering agent and cholesterol level-lowering agent useful in all aspects of the invention are those
15 that are commonly and routinely used for the treatment of vascular and cardiac disease. Relatedly, regimes for administration of the agents for use in the treatment of vascular and cardiac disease can be used in the various aspects of the present invention. Such agents typically are administered at doses of about 0.1 mg to about 1000 mg per day, and ideally at about 5 mg to about 100 mg per day. The
20 combinations to be employed can be formulated individually in their normal fashion (e.g., atorvastatin, troglitazone, rosiglitazone, gemfibrozil), or the agents can be formulated as a fixed dose combination, for example, an oral tablet containing 40 mg of atorvastatin and 200 mg of gemfibrozil or carboxyalkylether.

Administration of the agents recited in each aspect of the invention can be
25 conducted by the same methods the agents are administered to treat vascular and cardiac disease, which are widely known and commonly used.

The ability of the triglyceride level-lowering agents and the cholesterol level-lowering agents to prevent or delay the onset of AD has been established by the following detailed examples. The examples are provided for illustrative
30 purposes only, and are not intended to be limiting in any respect.

EXAMPLE 1

Apolipoprotein E is a 34 kDa amphipathic protein that associates with serum triglyceride-rich and high-density lipoproteins and is involved in the transport of cholesterol between tissues. Three isoforms of the ApoE protein that differ by one or two amino acids are found in the human population. The ApoE2, E3, and E4 are respectively coded by the genes ApoE ϵ 2, ϵ 3, and ϵ 4. Apolipoprotein E ϵ 4 represents a well-established risk factor for AD. Individuals with AD carrying the ApoE ϵ 4 allele have more profuse deposits of A β in the cerebral cortex and vascular walls than the other ApoE alleles. This implies that ApoE4 interactions with A β or its lipid transport function or both affect the accumulation of A β . The increased risk of cardiovascular disease conferred by ApoE4 is attributed to an associated hypercholesterolemia that can promote or exacerbate atherosclerosis, hypertension, myocardial infarction and critical coronary artery disease.

The following experiment investigated the relationship between AD and known risk factors for cardiovascular disease, including ApoE genotype, serum lipids, lipoproteins, and apolipoprotein levels. In addition, A β levels in the gray matter were determined. The results are discussed in terms of the implicit involvement of lipid metabolism in the pathophysiology of Alzheimer's Disease.

HUMAN SUBJECTS AND METHODOLOGY

Human Tissue. Sixty-four AD and 36 non-demented control brains were obtained from Sun Health Research Institute Brain Bank (postmortem-freezing delay 1-3 hours, average 2.1 hours). The brains from the demented patients fulfilled the diagnostic criteria of AD as dictated by the Consortium to Establish a Registry for Alzheimer's Disease (CERAD). The control cases had no clinical history of dementia or neurological symptoms, and on neuropathological examination did not meet the AD guidelines. Blood was collected in the immediate post-mortem by cardiac puncture from left ventricle.

ApoE genotyping. ApoE genotyping was carried out using standard techniques. Crude genomic DNA, prepared from white blood cell nuclei, was submitted to 40 cycles of polymerase chain reaction, and digested with restriction enzyme *HhaI* prior to electrophoresis on an 8% polyacrylamide gel.

5 *Quantitation of lipids.* Serum total cholesterol and triglycerides were determined enzymatically by standard procedures. Serum lipoprotein cholesterol profiles and distribution among lipoproteins were determined by on-line-post column analysis on Superose 6HR high performance gel filtration chromatography (HPGC). Lipoprotein cholesterol was determined by multiplying
10 the independently determined total serum cholesterol by the percent area for each lipoprotein distinctly separated by the HPGC method. ApoA-I, ApoE and ApoB levels were determined by immunoturbidometric methods using commercially available kits (Wako Chemical USA, Inc., Richmond, VA) on a Cobus Mira Plus analyzer (Roche Diagnostics Systems, Branchburg, NJ).

15 *Quantitation of brain cholesterol.* Brain lipids were extracted by standard methods. Briefly, 0.2 g of white or grey brain tissue, plus 100 µg of 4-cholesten-3-one (internal standard) was homogenized in 5 mL of chloroform/methanol (2:1, v/v) and then filtered through Whatman No. 1 filter paper. Another 2 mL of the chloroform/methanol mixture was used to re-extract the residue. Water (1.5 mL)
20 was added to the extract and centrifuged at 2000 g for 10 minutes to distinctly separate the biphasic. The lower chloroform phase containing the lipid extract was taken to dryness under nitrogen gas, and then dissolved in 1 mL of 2-propanol/hexane (1:19, v/v) for HPLC analysis. Brain cholesterol was separated by high pressure liquid chromatography (Thermo Separation Products, Fremont, CA)
25 from internal standard on a 5 µm silica normal phase column (Zorbax SIL, 4.6 × 250 mm) at a flow rate of 1 mL/minute. The relative absorbance values at 208 nm for the internal standard and cholesterol were considered in the final calculation of brain cholesterol.

30 *Europium immunoassay (EIA) of Aβ Peptides.* Cerebral cortex (0.8 g) from the superior frontal gyrus was minced and rinsed with buffer (20 mM Tris-HCl, pH 8.5) containing protease inhibitors. The tissue was homogenized in 3 mL of

buffer, spun at 100,000 g for 1 hour at 4°C and prepared for A β quantitation. One hundred microliters of the final diluted solution was submitted to EIA. Rabbit antibodies R163 and R165, raised against amino acids 34-40 and 36-42 of A β , respectively, were coated to microtiter plates. Wells were blocked with bovine serum albumin (1%) and 100 μ L of the specimens or of A β standards were

applied, incubated at room temperature for 2 hours, and then rinsed with 0.05% Tween 20-tris buffered saline (TTBS). Europium-labeled 4G8 antibody (against A β residue 17-24) was added to the wells, incubated for 2 hours and washed with TTBS, and rinsed with deionized water. Finally, the Eu enhancement solution (Wallac Inc., Gaithersburg, MD) was added and the plates read in a fluorimeter using excitation and emission wavelengths of 320 and 615 nm, respectively. The values, obtained from triplicated wells, were calculated based on standard curves generated on each plate.

Statistical Analysis. Two-tailed Student T-Test was applied when variable means were compared between control and AD subjects. Analysis of covariance (ANCOVA) of linear regression was used to estimate the relationships between two variables. The effects of ApoE genotype were determined by analysis of variance (ANOVA). Post-hoc multiple comparisons were only applied to those significant ANOVA groups. Significant differences between genotypes were determined by Fisher's Protected Least Significant Differences (PLSD) for the comparisons of multiple means.

RESULTS

Examination of the lipid profiles of AD versus control subjects reveals a significant elevation in the amount of total cholesterol (TC), primarily in higher concentration of LDL in the AD cases (Table 1). This difference can be appreciated by its frequency distribution, segmented by decile, as shown in Figure 1. In controls subjects, 81 percent (29 of 36 subjects) had LDL cholesterol

levels below the third decile (i.e., below 112 mg/dL), with all control subjects having LDL cholesterol below the fifth decile (i.e., below 163 mg/dL). In contrast, only 53 percent of the AD subjects fell below the third decile (36 of 68 subjects), while 21 percent (14 of 68 subjects) of these subjects had cholesterol above the fifth decile. Apolipoprotein B (ApoB), which is primarily associated with serum LDL, is also significantly elevated in AD (Table 1). Other lipids, such as VLDL-cholesterol, triglycerides (TG), ApoA-I, and ApoE, showed no significant differences between the AD and control groups (Table 1). In contrast, the levels of the HDL cholesterol, as well as the ratio of the HDL cholesterol to VLDL plus LDL cholesterol, were significantly higher in the control group than in the AD population (Table 1). As expected, the levels of A β N-40 and A β N-42 in brain were substantially higher in AD than those of control group (Table 1). When compared to the control group, the amount of brain white matter cholesterol in AD patients was less, as was the brain grey matter cholesterol, as shown in Figure 2.

Large population studies show an effect of ApoE isoforms on serum total and LDL cholesterol levels. In our cohort, serum cholesterol levels were also increased in ApoE ϵ 4 carriers; however, this elevation was not significant. The impact of ApoE genotype in this study is most evident on the amount of A β N-40 in AD brains (Figure 3A). The highest level of A β N-40 was found in AD patients homozygous for ApoE4, the amount being 20 times and 4 times greater than in those individuals with ApoE ϵ 3/ ϵ 3 and ϵ 3/ ϵ 4, respectively (Figure 3A). Any AD subjects carrying ApoE ϵ 4 had approximately twice the quantity of A β N-42 when compared to those AD cases lacking the ApoE ϵ 4 allele, as well as to all ApoE genotypes in the control group (Figure 3B). The sums of A β N-40 plus A β N-42 relative to each ApoE genotype are shown in Figure 3C. In AD subjects, the total A β linearly increased with the addition of one and two ApoE ϵ 4 alleles (Figure 3C). In all cases, total A β was significantly higher in the AD subjects

homozygous for ApoE4 than all other isoforms in either the AD or control cohorts (Figure 3C).

Significant associations between the levels of total serum cholesterol, LDL cholesterol and ApoB in AD subjects were seen with A β N-42 (Figures 4A-C),

5 but not A β N-40 (data not shown). The strongest correlation occurred between ApoB and A β N-42 (Figure 4C), where the "r" value is the correlation factor, $r = 1$

being a perfect 1:1 correlation. These data clearly establish that those AD subjects with higher levels of total serum cholesterol, LDL cholesterol and ApoB are more likely to have higher levels of A β N-42. In control subjects (C), virtually no
10 correlations were seen between these serum lipid parameters and A β N-42 levels (Figure 4A-C). The amounts of HDL also failed to show an association with A β N-42 in either control or AD brains (Figure 4D). These data establish that higher concentrations of total serum cholesterol leads to higher levels of β -amyloid peptide in AD brains.

15 The above study investigated whether factors associated with cardiovascular disease, such as high levels of serum total cholesterol, LDL cholesterol and low levels of HDL cholesterol, were associated with AD. The results establish that total serum and LDL cholesterol, as well as ApoB levels, are associated with increased deposition of A β N-42 in demented individuals with
20 neuropathologically confirmed AD. The brain deposition of A β N-42 was significantly correlated with serum total and LDL cholesterol, and ApoB in the AD, but not in control subjects. There were also a disproportionate number of AD (47%) compared to control (18%) subjects with LDL cholesterol greater than 112 mg/dL (i.e., above the third decile for LDL cholesterol).

25 It is well-recognized that ApoE4 increases amyloid load in AD brain. The present data establish that the level of A β N-40 in AD brains appears governed almost exclusively by the presence of ApoE ϵ 4. A β N-40 increases from 1.2 to 6.0 to 24.1 μ g/g for 0, 1 and 2 copies of the ApoE ϵ 4 allele, respectively. A similar

but less dramatic trend is also observed for A β N-42. Immunological techniques have revealed an association between ApoE ϵ 4 and higher concentrations of A β N-40 in AD cerebral cortex, and also between ApoE ϵ 4 and vascular amyloid. Since most of A β N-40 is found in the cerebrovasculature, the foregoing data show that the presence of ApoE4 affects deposition of A β in blood vessels. The cerebrovascular amyloidosis observed in AD destroys the myocytes of small arteries and arterioles and obliterates the capillary network resulting in severe damage to cerebral blood flow. This compromise leads to neuronal damage through ischemia and hypoxia. Thus, ApoE ϵ 4 may increase the risk of developing AD and accelerate its age of onset through indirect consequences on vessels in the brain.

Several lines of evidence have already suggested that cholesterol, or cholesterol metabolism, might influence susceptibility to AD. Two previous clinical studies showed that total serum or LDL cholesterol was elevated in patients with AD. In addition, individuals with ApoE ϵ 4, a recognized risk factor for cardiovascular disease and AD, also tend to manifest hypercholesterolemia. Moreover, the incidence of AD appears to be higher in countries with high fat and caloric diets, and decreased in populations ingesting diets that decrease cardiovascular disease. Epidemiological investigations have further demonstrated that the risk for AD was greater in individuals with elevated cholesterol levels, and that the onset of AD occurred earlier in those individuals who were ApoE ϵ 4 carriers with high serum cholesterol.

Table 1. Comparison Between AD and Control Subjects With Respect to Serum Lipids and Brain Tissue A β N-40 and A β N-42

	AD (n = 64)	Control (n = 36)	P value*
age (years)	81.6 \pm 0.9	78.7 \pm 1.3	0.054
TC (mg/dL)	176.0 \pm 8.2	152.8 \pm 7.1	0.061
VLDL-C (mg/dL)	18.6 \pm 2.0	17.0 \pm 2.0	0.619
LDL-C (mg/dL)	124.0 \pm 7.0	95.5 \pm 5.0	0.006
HDL-C (mg/dL)	35.0 \pm 1.8	42.3 \pm 3.7	0.040
HDL-C/(VLDL-C+LDL-C)	0.31 \pm 0.03	0.41 \pm 0.04	0.048
TG (mg/dL)	225.3 \pm 12.6	201.4 \pm 16.0	0.249
ApoA-I (mg/dL)	100.0 \pm 3.3	108.2 \pm 5.1	0.162
ApoB (mg/dL)	91.8 \pm 4.4	76.6 \pm 3.1	0.018
ApoE (mg/dL)	4.8 \pm 0.3	5.0 \pm 0.4	0.753
A β N-40 (μ g/g)	7.47 \pm 2.05	1.11 \pm 0.56	0.024
A β N-42 (μ g/g)	18.2 \pm 1.7	7.87 \pm 1.68	<0.001
A β Total (μ g/g)	25.7 \pm 2.8	9.0 \pm 1.9	<0.001

TC = Total serum cholesterol; VLDL-C = Very low density lipoprotein cholesterol; LDL-C = Low density lipoprotein cholesterol; HDL-C = High density lipoprotein cholesterol; TG = Triglycerides.

* Two-tailed Student T-test probability

EXAMPLE 2

This experiment was designed to determine the ability of lipid regulating agents to alter the production of β -amyloid peptide (A β) in cultured cells, and their consequent activity in preventing and treating Alzheimer's Disease.

- 5 Chinese hamster ovary (CHO) cells were stably transfected with a construct to enable the overexpression of the human β -amyloid precursor protein (β APP) gene to cause increased production of A β . The measurement of A β synthesized by these β APP-CHO cells was done using a standard sandwich ELISA assay, employing well-characterized antibodies to the N-terminus (6E10) and middle (4G8) of A β . This assay is routinely used to measure A β in tissues, 10 body fluids, and cell culture media.

Cultures of β APP-CHO cells were grown to near confluency, and then the test compounds were added at various dose concentrations to the cell medium.

Figure 5 shows the dramatic reduction in $A\beta$ caused by several statins.

5 Mevastatin, lovastatin, and simvastatin all caused a dramatic dose-dependent reduction in $A\beta$. Pravastatin caused a dose-dependent reduction in $A\beta$ as well, albeit somewhat less pronounced.

Several other lipid-regulating agents were evaluated in the β APP-CHO cells. Avasimibe (CI-1011) caused a substantial dose-dependent reduction in $A\beta$, as shown in Figure 6. PD 69405, CI-1027, and CI-719 caused only moderate
10 changes at the concentrations tested.

EXAMPLE 3

The following experiment established that lipid regulating agents cause a reduction in insoluble fibrillar $A\beta$ N-42 in the brains of animals.

15 Mice aged 24 months were fed a high fat (15%) high cholesterol (1.25%) diet containing 0.5% cholic acid (High Fat) or regular rodent chow (chow) for 4 weeks. During the last 2 weeks of the study, two groups of mice were given 10 mg/kg simvastatin daily by oral gavage. Mice were then sacrificed by anesthetic overdose perfused with cold 0.9% saline via heart puncture. The saline rinsed brain was then removed from the skull and frozen over dry ice. The brain
20 samples were stored at -80°C until assayed for $A\beta$ N-40 and $A\beta$ N-42.

On the day of assay, brains were thawed and the hippocampus and cortex were dissected from the rest of the brain. These samples were dounce homogenized in tris-buffered saline (TBS) containing protease inhibitor cocktail (PIC) and 0.5 mM ethylene diamine tetraacetic acid (EDTA). The samples were
25 centrifuged at 100,000XG for 1 hour. The supernatants were drawn off, and the remaining pellet was treated with 0.2% diethylamine buffer in 50 mM saline. The pellet was re-suspended in diethylamine (DEA) by probe sonication, and the samples were centrifuged again at 100,000XG for 1 hour. The DEA extracted supernatant samples were drawn off and neutralized to pH 8.0 by the addition of
30 2 M tris-HCl buffer. The amount of $A\beta$ N-40 and $A\beta$ N-42 were measured in these samples by ELISA. In addition, a protein assay was run on each sample so


that variations in sample size could be normalized by protein content. Thus, A β values are expressed in ng/mg protein.

5 Table 7 shows that the lipid regulating agent simvastatin (S) caused a substantial reduction in A β N-42 in all animals, compared to non-treated controls (C). The animals having the High Fat diet exhibited slightly less inhibition of A β N-42 than the Chow fed animals. The compound had only marginal effect on A β N-40.

CLAIMS

What is claimed is:

1. A method of treating Alzheimer's Disease comprising administering to a human suffering from the disease an effective Alzheimer's Disease-alleviating amount of a plasma-triglyceride level-lowering agent.
2. A method of treating Alzheimer's Disease comprising administering to a human suffering from the disease an effective Alzheimer's Disease-alleviating amount of a plasma-triglyceride level-lowering agent, wherein the plasma-triglyceride level-lowering agent is selected from the group consisting of fibrates, thazolinediones, niacin, EPA, and compositions containing one or more of the foregoing.
3. A method of treating Alzheimer's Disease comprising administering to a human suffering from the disease an effective Alzheimer's Disease-alleviating amount of a plasma-triglyceride level-lowering agent, wherein the agent is clofibrate, gemfibrozil, fenofibrate, ciprofibrate, bezafibrate, niacin, EPA or:



wherein

n and m independently are integers from 2 to 9;


R₁, R₂, R₃, and R₄ independently are C₁-C₆ alkyl, C₂-C₆ alkenyl,

C₂-C₆ alkynyl, and R₁ and R₂ together with the carbon to which they are attached, and R₃ and R₄ together with the carbon to which they are attached, can complete a carbocyclic ring having from 3 to 6 carbons;

Y₁ and Y₂ independently are COOH, CHO, tetrazole, and

COOR₅ where R₅ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl;
and where the alkyl, alkenyl, and alkynyl groups may be substituted with
one or two groups selected from halo, hydroxy, C₁-C₆ alkoxy, and phenyl
or compositions comprising one or more of the foregoing.

- 5 4. The method according to Claim 3, wherein the plasma-triglyceride level-
lowering agent is:



- 10 5. A method of treating Alzheimer's Disease comprising administering to a
human suffering from the disease an effective Alzheimer's Disease-
alleviating amount of a plasma-triglyceride level-lowering agent, wherein
the agent is co-administered with an effective plasma cholesterol
level-lowering amount of a plasma cholesterol level-lowering agent.
- 15 6. A method of treating Alzheimer's Disease comprising administering to a
human suffering from the disease an effective Alzheimer's Disease-
alleviating amount of a plasma-triglyceride level-lowering agent, wherein
the agent is co-administered with an effective plasma cholesterol
level-lowering amount of a plasma cholesterol level-lowering agent,
wherein the plasma cholesterol level-lowering agent is selected from the
group consisting of statins, bile acid sequestrants, and agents that block
20 intestinal cholesterol absorption.
- 25 7. A method of treating Alzheimer's Disease comprising administering to a
human suffering from the disease an effective Alzheimer's Disease-
alleviating amount of a plasma-triglyceride level-lowering agent, wherein
the agent is co-administered with an effective plasma cholesterol level-
lowering amount of a plasma cholesterol level-lowering agent, wherein the

5 plasma cholesterol level-lowering agent is selected from the group consisting of statins, bile acid sequestrants, and agents that block intestinal cholesterol absorption, wherein the plasma cholesterol level-lowering agent is mevastatin, simvastatin, pravastatin, atorvastatin, cenvastatin, fluvastatin, lovastatin, cholestyramine and colestipol.

8. A method of treating Alzheimer's Disease comprising administering to a human suffering from the disease an effective Alzheimer's Disease-alleviating amount of a plasma-triglyceride level-lowering agent, wherein the agent is clofibrate, gemfibrozil, fenofibrate, ciprofibrate, bezafibrate, niacin, EPA or, wherein the agent is co-administered with an effective plasma cholesterol level-lowering amount of a plasma cholesterol level-lowering agent.


9. A method of treating Alzheimer's Disease comprising administering to a human suffering from the disease an effective Alzheimer's Disease-alleviating amount of a plasma-triglyceride level-lowering agent, wherein the agent is clofibrate, gemfibrozil, fenofibrate, ciprofibrate, bezafibrate, niacin, EPA or, wherein the agent is co-administered with an effective plasma cholesterol level-lowering amount of a plasma cholesterol level-lowering agent, wherein the plasma cholesterol level-lowering agent is mevastatin, simvastatin, pravastatin, atorvastatin, cenvastatin, fluvastatin, lovastatin, cholestyramine, and colestipol.

10. A method of preventing the onset of Alzheimer's Disease comprising administering to a human an effective Alzheimer's Disease-preventing amount of a plasma-triglyceride level-lowering agent.

11. A method of preventing the onset of Alzheimer's Disease comprising administering to a human an effective Alzheimer's Disease-preventing amount of a plasma-triglyceride level-lowering agent, wherein the plasma-triglyceride level-lowering agent is selected from the group consisting of

fibrates, thazolinediones, niacin, EPA, and compositions containing one or more of the foregoing.

12. A method of preventing the onset of Alzheimer's Disease comprising administering to a human an effective Alzheimer's Disease-preventing amount of a plasma-triglyceride level-lowering agent, wherein the plasma-triglyceride level-lowering agent is selected from the group consisting of fibrates, thazolinediones, niacin, EPA, and compositions containing one or more of the foregoing, wherein the agent is clofibrate, gemfibrozil, fenofibrate, ciprofibrate, bezafibrate, niacin, EPA, or:



wherein

n and m independently are integers from 2 to 9;

R₁, R₂, R₃, and R₄ independently are C₁-C₆ alkyl, C₂-C₆ alkenyl,

C₂-C₆ alkynyl, and R₁ and R₂ together with the carbon to which

they are attached, and R₃ and R₄ together with the carbon to which

they are attached, can complete a carbocyclic ring having from 3 to 6 carbons;


Y₁ and Y₂ independently are COOH, CHO, tetrazole, and

COOR₅ where R₅ is C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl;

and where the alkyl, alkenyl, and alkynyl groups may be substituted with one or two groups selected from halo, hydroxy, C₁-C₆ alkoxy, and phenyl or compositions containing one or more of the foregoing.

13. A method of preventing the onset of Alzheimer's Disease comprising administering to a human an effective Alzheimer's Disease-preventing amount of a plasma-triglyceride level-lowering agent, wherein the plasma-triglyceride level-lowering agent is selected from the group consisting of fibrates, thazolinediones, niacin, EPA, and compositions containing one or

more of the foregoing, wherein the agent is clofibrate, gemfibrozil, fenofibrate, ciprofibrate, bezafibrate, niacin, EPA, or wherein the plasma-triglyceride level-lowering agent is:



- 5 14. A method of preventing the onset of Alzheimer's Disease comprising
administering to a human an effective Alzheimer's Disease-preventing
amount of a plasma-triglyceride level-lowering agent, wherein the agent is
co-administered with an effective plasma cholesterol level-lowering
amount of a plasma cholesterol level-lowering agent.
- 10 15. A method of preventing the onset of Alzheimer's Disease comprising
administering to a human an effective Alzheimer's Disease-preventing
amount of a plasma-triglyceride level-lowering agent, wherein the agent is
co-administered with an effective plasma cholesterol level-lowering
amount of a plasma cholesterol level-lowering agent, wherein the plasma
15 cholesterol level-lowering agent is selected from the group consisting of
statins, bile acid sequestrants, and agents that block intestinal cholesterol
absorption.
- 20 16. A method of preventing the onset of Alzheimer's Disease comprising
administering to a human an effective Alzheimer's Disease-preventing
amount of a plasma-triglyceride level-lowering agent, wherein the agent is
co-administered with an effective plasma cholesterol level-lowering
amount of a plasma cholesterol level-lowering agent, wherein the plasma
cholesterol level-lowering agent is selected from the group consisting of
statins, bile acid sequestrants, and agents that block intestinal cholesterol
25 absorption, wherein the plasma cholesterol level-lowering agent is

mevastatin, simvastatin, pravastatin, atorvastatin, cenvastatin, fluvastatin, lovastatin, cholestyramine, and colestipol.

17. A method of preventing the onset of Alzheimer's Disease comprising administering to a human an effective Alzheimer's Disease-preventing amount of a plasma-triglyceride level-lowering agent, wherein the plasma-triglyceride level-lowering agent is selected from the group consisting of fibrates, thazolinediones, niacin, EPA, and compositions containing one or more of the foregoing, wherein the agent is clofibrate, gemfibrozil, fenofibrate, ciprofibrate, bezafibrate, niacin, EPA, or wherein the agent is co-administered with an effective plasma cholesterol level-lowering amount of a plasma cholesterol level-lowering agent.
18. A method of preventing the onset of Alzheimer's Disease comprising administering to a human an effective Alzheimer's Disease-preventing amount of a plasma-triglyceride level-lowering agent, wherein the plasma-triglyceride level-lowering agent is selected from the group consisting of fibrates, thazolinediones, niacin, EPA, and compositions containing one or more of the foregoing, wherein the agent is clofibrate, gemfibrozil, fenofibrate, ciprofibrate, bezafibrate, niacin, EPA, or wherein the agent is co-administered with an effective plasma cholesterol level-lowering amount of a plasma cholesterol level-lowering agent, wherein the plasma cholesterol level-lowering agent is mevastatin, simvastatin, pravastatin, atorvastatin, cenvastatin, fluvastatin, lovastatin, cholestyramine, and colestipol.
19. A method of preventing the onset of Alzheimer's Disease comprising administering to a human an effective Alzheimer's Disease-preventing amount of a plasma-triglyceride level-lowering agent wherein the plasma-triglyceride level-lowering agent is selected from the group consisting of fibrates, thazolinediones, niacin, EPA, and compositions containing one or more of the foregoing, wherein the agent is clofibrate, gemfibrozil, fenofibrate, ciprofibrate, bezafibrate, niacin, EPA, or wherein the plasma-


triglyceride level-lowering agent is, wherein the agent is co-administered with an effective plasma cholesterol level-lowering amount of a plasma cholesterol level-lowering agent.

- 5 20. A method of preventing the onset of Alzheimer's Disease comprising administering to a human an effective Alzheimer's Disease-preventing amount of a plasma-triglyceride level-lowering agent, wherein the plasma-
-
- 10 triglyceride level-lowering agent is selected from the group consisting of fibrates, thazolinediones, niacin, EPA, and compositions containing one or more of the foregoing, wherein the agent is clofibrate, gemfibrozil, fenofibrate, ciprofibrate, bezafibrate, niacin, EPA, or wherein the plasma-
- 15 triglyceride level-lowering agent is, wherein the agent is co-administered with an effective plasma cholesterol level-lowering amount of a plasma cholesterol level-lowering agent, wherein the plasma cholesterol level-lowering agent is mevastatin, simvastatin, pravastatin, atorvastatin, cenvastatin, fluvastatin, lovastatin, cholestyramine, and colestipol.
21. A method of treating Alzheimer's Disease comprising administering to a human suffering from the disease an effective Alzheimer's Disease-alleviating amount of one or more agents that lower plasma triglyceride levels and LDLC levels and increase HDL levels.
- 20 22. A method of preventing the onset of Alzheimer's Disease comprising administering to a human an effective Alzheimer's Disease-preventing amount of one or more agents that lower plasma triglyceride levels and LDLC levels and increase HDL levels.
- 25 23. A method of treating Alzheimer's Disease comprising administering to a human suffering from the disease an effective Alzheimer's Disease-alleviating amount of one or more agents that increase HDL-C levels.


24. A method of preventing the onset of Alzheimer's Disease comprising administering to a human an effective Alzheimer's Disease-preventing amount of one or more agents that increase HDL-C levels.
- 5 25. A method of treating Alzheimer's Disease comprising administering to a human suffering from the disease an effective Alzheimer's Disease-alleviating amount of one or more agents that increase HDL-C levels,
-
- further comprising co-administering an effective Alzheimer's Disease-alleviating amount of one or more agents that lower plasma LDL-C levels.
- 10 26. A method of preventing the onset of Alzheimer's Disease comprising administering to a human an effective Alzheimer's Disease-preventing amount of one or more agents that increase HDL-C levels, further comprising co-administering an effective Alzheimer's Disease-preventing amount of one or more agents that lower plasma LDL-C levels.

1/20

FIG-1




2/20




3/20

FIG-2B




4/20

FIG-3A




5/20

FIG-3B




6/20

FIG-3C




7/20

FIG-4A




8/20

FIG-4B




9/20

FIG-4C




10/20


FIG-4D



11/20


FIG-5A DOSE RESPONSE WITH MEVASTATIN

12/20

FIG-5B DOSE RESPONSE WITH LOVASTATIN


13/20

FIG-5C DOSE RESPONSE WITH PRAVASTATIN




14/20

FIG-5D DOSE RESPONSE WITH SIMVASTATIN




15/20

FIG-6A BAPP CHO CELLS TREATED OVERNIGHT AT 37° WITH COMPOUND;
4G8/b6E10 ELISA ON MEDIA




16/20

FIG-6B
BAPP CHO CELLS TREATED OVERNIGHT AT 37° WITH COMPOUND;
4G8/b6E10 ELISA ON MEDIA




17/20

FIG-6C β APP CHO CELLS TREATED OVERNIGHT AT 37° WITH COMPOUND;
4G8/b6E10 ELISA ON MEDIA




18/20


FIG-6D βAPP CHO CELLS TREATED OVERNIGHT AT 37° WITH COMPOUND;
4G8/b6E10 ELISA ON MEDIA



19/20



20/20



INTERNATIONAL SEARCH REPORT

Int. Jonal Application No

PCT/US 98/25495

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/00 A61K31/215 A61K31/19 A61K31/195 A61K31/455
A61K31/20 A61K45/06 A61K31/425

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
------------	--	-----------------------

P, X	WO 98 39967 A (GEN HOSPITAL CORP ;ESMOND ROBERT W (US); WANDS JACK R (US); MONTE) 17 September 1998 see abstract see page 6, line 1 - line 10 see page 7, line 7 - line 26; claims ---	1-3, 5, 8-14, 17-20
P, X	WO 98 16216 A (SCOTIA HOLDINGS PLC ;HORROBIN DAVID F (GB)) 23 April 1998 see the whole document ---	1-3, 8-13, 17-20

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 April 1999

Date of mailing of the international search report

27/04/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hoff, P

INTERNATIONAL SEARCH REPORT

Int. Jonal Application No
PCT/US 98/25495

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95 06470 A (MERCK & CO INC ;SCOLNICK EDWARD M (US)) 9 March 1995 cited in the application	1,5-7, 10, 14-16, 21-26
Y	see the whole document	2,3,8,9, 11-13, 17-20
Y	--- B. LEININGER-MULLER ET AL.: "The rat, a useful animal model for pharmacological studies on apolipoprotein E" LIFE SCIENCES, vol. 58, no. 6, 1996, pages 455-467, XP002099552 see abstract see page 461, paragraph 8 - page 462, last paragraph	2,3,8,9, 11-13, 17-20
Y	--- M. YAMADA: "Influence of Apolipoprotein E Polymorphism on Bezafibrate Treatment Response in Dyslipidemic Patients" JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, vol. 4, no. 1, 1997, pages 40-44, XP002099553 see the whole document	2,3,8,9, 11-13, 17-20
A	--- J.E.F. REYNOLDS: "MARTINDALE, The Extra Pharmacopoeia" 1996 , ROYAL PHARMACEUTICAL SOCIETY , LONDON XP002099557 see page 1299 - page 1301 see page 1308 - page 1314	1-26
X	--- EP 0 814 080 A (PFIZER) 29 December 1997 see abstract see page 2, line 50 - page 9, line 42 see page 22, line 10 - line 37 see claims 1-29	1,5,10, 14
X	--- WO 97 48701 A (HAMANAKA ERNEST SEIICHI ;PFIZER (US); HAYWARD CHERYL MYERS (US)) 24 December 1997 cited in the application see abstract see page 3, line 1 - page 21, line 29 see page 46, line 27 - page 48, line 2; claims	1,5,10, 14
	--- -/--	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/25495

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 97 46238 A (GLAXO GROUP LTD ;COMINACINI LUCIANO (IT)) 11 December 1997</p> <p>see abstract see page 2, line 11 - line 13 see page 5, line 23 - page 6, line 2; claims</p>	1,2,5, 10-14, 17-20
X	<p>DATABASE WPI Section Ch, Week 9632 Derwent Publications Ltd., London, GB; Class B05, AN 96-318846 XP002099558 & JP 08 143454 A (KANAGAWA KAGAKU KENKYUJO KK), 4 June 1996 see abstract</p>	1-3, 8-13, 17-20
X	<p>F. SCHNEIDER ET AL.: "Superiority of Antagonist-Stress Composition versus Nicergoline in Gerontopsychiatry" ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, vol. 717, 1994, pages 332-342, XP002099554 see the whole document</p>	1-3, 8-13, 17-20
X	<p>WO 92 20335 A (INNOVATIVE TECH CENTER) 26 November 1992</p> <p>see abstract see page 7, line 1 - line 7; examples see page 40, line 24 - line 26; claims</p>	1,2, 10-13, 17-20
A	<p>WO 96 30328 A (WARNER LAMBERT CO) 3 October 1996 cited in the application see abstract; claims; examples</p>	3,4,12, 13
A	<p>K.M. HEILMAN ET AL.: "Hyperlipidemic Dementia" ARCHIVES OF NEUROLOGY, vol. 31, no. 1, 1974, pages 67-68, XP002099555 see the whole document</p>	1-26
A	<p>J-L. MAS ET AL.: "Hyperlipidemic Dementia" NEUROLOGY, vol. 35, no. 9, 1985, pages 1385-1387, XP002099556 see the whole document</p>	1-26

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/25495

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-26
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1-26
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☒ Claims Nos.: -
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
See FURTHER INFORMATION SHEET PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/25495

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9839967 A	17-09-1998	NONE	
WO 9816216 A	23-04-1998	AU 4566797 A	11-05-1998
WO 9506470 A	09-03-1995	AU 7397094 A US 5368404 A	22-03-1995 29-11-1994
EP 0814080 A	29-12-1997	CA 2208174 A JP 10059953 A	20-12-1997 03-03-1998
WO 9748701 A	24-12-1997	AU 2401697 A	07-01-1998
WO 9746238 A	11-12-1997	AU 3038997 A	05-01-1998
WO 9220335 A	26-11-1992	US 5122539 A US 5248785 A CA 2109575 A EP 0585366 A JP 7508973 T US 5290803 A US 5250701 A US 5432191 A US 5731454 A US 5591892 A US 5661182 A US 5677330 A US 5648375 A US 5705521 A	16-06-1992 28-09-1993 26-11-1992 09-03-1994 05-10-1995 01-03-1994 05-10-1993 11-07-1995 24-03-1998 07-01-1997 26-08-1997 14-10-1997 15-07-1997 06-01-1993
WO 9630328 A	03-10-1996	US 5648387 A AU 692359 B AU 4776896 A BG 101993 A CA 2215233 A CN 1182415 A CZ 9702922 A EP 0820428 A FI 973713 A HU 9801825 A JP 11502532 T NO 974397 A PL 322407 A US 5750569 A US 5783600 A US 5756544 A	15-07-1997 04-06-1998 16-10-1996 29-05-1998 03-10-1996 20-05-1998 14-10-1998 28-01-1998 24-09-1997 28-12-1998 02-03-1999 20-11-1997 19-01-1998 12-05-1998 21-07-1998 26-05-1998